Killing colon cancer cells through PCD pathways by a novel hyaluronic acid-modified shell-core nanoparticle loaded with RIP3 in combination with chloroquine

Hou, Xueyan; Yang, Chengli; Zhang, Lijing; Hu, Tingting; Sun, Dan; Cao, Hua; Yang, Fan; Guo, Gang; Gong, Changyang; Zhang, Xiaoning; Tong, Aiping; Li, Rui; Zheng, Yu

doi:10.1016/j.biomaterials.2016.12.032

Cited by 60 publications

(34 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RIPK3 and/or MLKL might be restored by using liposomes and polymer‐based nanoparticles containing either mRNA of RIPK3 or MLKL, which are among the most representative strategies of drug‐delivery systems. A recent study has shown that the growth of CT26 tumor cells can be attenuated in vivo by targeted delivery of mRIPK3‐pDNA within hyaluronic acid‐modified lipid‐coated nanoparticles . The anti‐tumor effect was increased when RIPK3 was loaded in these nanoparticles together with cloroquine, pointing to the efficacy of the delivery system and the importance of combination therapy.…”

Section: Future Perspectivesmentioning

confidence: 99%

“…A recent study has shown that the growth of CT26 tumor cells can be attenuated in vivo by targeted delivery of mRIPK3-pDNA within hyaluronic acid-modified lipid-coated nanoparticles. 111 The anti-tumor effect was increased when RIPK3 was loaded in these nanoparticles together with cloroquine, pointing to the efficacy of the delivery system and the importance of combination therapy. Alternatively, necroptosis resistance might be overcome by triggering other regulated forms of necrosis, such as ferroptosis (Table 1).…”

Section: Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Necroptotic cell death in anti‐cancer therapy

Krysko

Aaes

Kagan

et al. 2017

Immunological Reviews

141

103

View full text Add to dashboard Cite

Necroptosis is one the best-characterized forms of regulated necrosis. Necroptosis is mediated by the kinase activities of receptor interacting protein kinase-1 and receptor interacting protein kinase-3, which eventually lead to the activation of mixed lineage kinase domain-like. Necroptosis is characterized by rapid permeabilization of the plasma membrane, which is associated with the release of the cell content and subsequent exposure of damage-associated molecular patterns (DAMPs) and cytokines/chemokines. This release underlies the immunogenic nature of necroptotic cancer cells and their ability to induce efficient anti-tumor immunity. Triggering necroptosis has become especially important in experimental cancer treatments as an alternative to triggering apoptosis because one of the hallmarks of cancer is the blockade or evasion of apoptosis. In this review, we discuss recent advances in necroptosis research and the functional consequences of necroptotic cancer cell death, with focus on its immunogenicity and its role in the activation of anti-tumor immunity. Next, we discuss the molecular mechanisms of phosphatidylserine exposure during necroptosis and its role in the recognition of necroptotic cells. We also highlight the complex role of the necroptotic pathway in tumor promotion and suppression and in metastasis. Future studies will show whether necroptosis is truly a better strategy to overcome apoptosis resistance and provide the insights needed for development of novel treatment strategies for cancer.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

Section: Future Perspectivesmentioning

confidence: 99%

Necroptotic cell death in anti‐cancer therapy

Krysko

Aaes

Kagan

et al. 2017

Immunological Reviews

141

103

View full text Add to dashboard Cite

show abstract

“…22 The overexpression of HA-binding receptor, such as CD44, has been found on the cell surface of some malignant tumors, which brings about the broad applications of HA-based NP in active tumor targeting for anticancer drugs. 23 In the present study, to prepare the actively tumor-targeted delivery carrier, the HA was conjugated onto the surfaces of SeNPs to fabricate the HA-Se NP. Then, the positively charged polycationic polymer polyethylenimine (PEI) was conjugated onto the surfaces of SeNPs for binding with siRNA.…”

Section: Introductionmentioning

confidence: 99%

siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy

Xia¹,

Guo²,

Xu³

et al. 2018

IJN

View full text Add to dashboard Cite

Background Small interfering RNA (siRNA) as a new therapeutic modality holds promise for cancer treatment. However, the traditional viral carriers are prone to immunogenicity and risk of insertional mutagenesis. Methods In order to provide a tumor-targeted delivery carrier of siRNA in cancer therapy, the hyaluronic acid (HA)-selenium (Se)-polyethylenimine (PEI) nanoparticle (NP) was fabricated by decorating SeNP with HA as a tumor-targeting moiety and by linking the polycationic polymers polyethylenimine PEI onto the surface of SeNP. The siRNA was loaded to the surface of SeNP HA-Se-PEI via the electrostatic interaction between siRNA and PEI to prepare the functionalized SeNP HA-Se-PEI@siRNA. Results The HA-Se-PEI@siRNA was internalized into the HepG2 cell mainly in a clathrin-mediated endocytosis manner. Owing to the active tumor-targeted effect mediated by HA, HA-Se-PEI@siRNA achieved the obvious higher transfection efficiency, greater gene silencing ability, and stronger cytotoxicity in the HepG2 cell compared with the passive tumor-targeted NP Se-PEI@siRNA. The knockdown of hairy and enhancer of split 5 by HA-Se-PEI@siRNA induced the HepG2 cell cycle arrest at the G0/G1 phase and apoptosis. Furthermore, the treatment with HA-Se-PEI@siRNA resulted in greater antitumor efficacy compared with the Se-PEI@siRNA in vitro and in vivo. In addition, the HA-Se-PEI@siRNA was almost no toxic to the key organs of mice. Conclusion These findings provided an alternative therapeutic route for targeted cancer treatments.

show abstract

“…Thiolated-PEG-COOH functionalized gold nanoparticles were also reported to deliver biohybrid RNAi-peptide specifically to the cancer cells [10]. Similarly, various functionalized gold, platinum nanoparticles, quantum dots, lipidated particles, liposomes, and dendrimers have been used extensively for targeted drug delivery, imaging and cancer cell killing [11–16]. Among these nanomaterials, selenium nanoparticles (SeNPs) are reported to be the most promising nanosystem which itself has high anticancer activity and better biocompatibility [17, 18].…”

Section: Introductionmentioning

confidence: 99%

Biogenic selenium nanoparticles induce ROS-mediated necroptosis in PC-3 cancer cells through TNF activation

2017

View full text Add to dashboard Cite

BackgroundSelenium is well documented to inhibit cancer at higher doses; however, the mechanism behind this inhibition varies widely depending on the cell type and selenium species. Previously, we have demonstrated that Bacillus licheniformis JS2 derived biogenic selenium nanoparticles (SeNPs) induce non-apoptotic cell death in prostate adenocarcinoma cell line, PC-3, at a minimal concentration of 2 µg Se/ml, without causing toxicity to the primary cells. However, the mechanism behind its anticancer activity was elusive.ResultsOur results have shown that these SeNPs at a concentration of 2 µg Se/ml were able to induce reactive oxygen species (ROS) mediated necroptosis in PC-3 cells by gaining cellular internalization. Real-time qPCR analysis showed increased expression of necroptosis associated tumor necrotic factor (TNF) and interferon regulatory factor 1 (IRF1). An increased expression of RIP1 protein was also observed at the translational level upon SeNP treatment. Moreover, the cell viability was significantly increased in the presence of necroptosis inhibitor, Necrostatin-1.ConclusionData suggest that our biogenic SeNPs induce cell death in PC-3 cells by the ROS-mediated activation of necroptosis, independent to RIP3 and MLKL, regulated by a RIP1 kinase.

show abstract

Killing colon cancer cells through PCD pathways by a novel hyaluronic acid-modified shell-core nanoparticle loaded with RIP3 in combination with chloroquine

Cited by 60 publications

References 81 publications

Necroptotic cell death in anti‐cancer therapy

Necroptotic cell death in anti‐cancer therapy

siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy

Biogenic selenium nanoparticles induce ROS-mediated necroptosis in PC-3 cancer cells through TNF activation

Contact Info

Product

Resources

About